Among KRAS mutant lung cancer cell lines, KRAS G12D preferentially activates MAPK signaling, while KRAS G12C or G12V mutants activate Ral signaling and exhibit decreased growth factor-dependent activation of the PI3K pathway [12]. The gene discussed is KRAS; the disease is lung cancer.